Immunotherapy Clinical Trials

95 recruiting

Immunotherapy Trials at a Glance

141 actively recruiting trials for immunotherapy are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 62 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Shanghai. Lead sponsors running immunotherapy studies include Sun Yat-sen University, Shanghai Juncell Therapeutics, and Fudan University.

Browse immunotherapy trials by phase

Treatments under study

About Immunotherapy Clinical Trials

Looking for clinical trials for Immunotherapy? There are currently 95 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunotherapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunotherapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 141 trials

Recruiting
Phase 1

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

Acute Myeloid LeukemiaMaintenance TherapyPersonalized Active Immunotherapy
Fujian Medical University Union Hospital90 enrolled1 locationNCT07551037
Recruiting

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

CancerQuality of LifeDistress, Emotional+4 more
Taipei Veterans General Hospital, Taiwan200 enrolled1 locationNCT06461780
Recruiting

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NSCLCNeoadjuvant ChemoimmunotherapyCT
Samsung Medical Center150 enrolled1 locationNCT07559123
Recruiting

IMMUNO-FIT Observational Study

Quality of LifeNeoplasmsImmunotherapy+2 more
University Hospital Southampton NHS Foundation Trust67 enrolled1 locationNCT07354971
Recruiting
Phase 2

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

ChemotherapyRectal CancerRadiotherapy+1 more
Tao Zhang25 enrolled1 locationNCT07239466
Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting
Phase 3

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Esophageal CarcinomaRadiotherapyImmunotherapy
Fudan University452 enrolled1 locationNCT06964568
Recruiting

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

Stage IIB-III NSCLCNeoadjuvant ChemoimmunotherapyRobotic Pulmonary Resection
Shanghai Chest Hospital200 enrolled10 locationsNCT07528066
Recruiting
Phase 4

Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation

ImmunotherapyAllergyVenom Allergy
Murdoch Childrens Research Institute100 enrolled3 locationsNCT06935890
Recruiting
Phase 2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Hepatocellular CarcinomaRadiotherapyImmunotherapy+3 more
Shandong Cancer Hospital and Institute54 enrolled1 locationNCT07062055
Recruiting
Phase 2

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Bladder CancerImmunotherapyLiquid Biopsy
Tianjin Medical University Second Hospital53 enrolled1 locationNCT07475403
Recruiting
Phase 2

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

Acute Lymphoblastic LeukemiaImmunotherapyBlinatumomab+1 more
The First Affiliated Hospital of Soochow University26 enrolled1 locationNCT06985485
Recruiting
Phase 2

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

NSCLCImmunotherapyStereotactic Body Radiation Therapy (SBRT)
Fudan University27 enrolled1 locationNCT06738160
Recruiting
Not Applicable

Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer

Breast Cancer (Locally Advanced or Metastatic)Neoadjuvant ChemoimmunotherapyTattoo Skin Markers
All India Institute of Medical Sciences, Bhubaneswar30 enrolled1 locationNCT07478900
Recruiting
Phase 2

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting

Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy

Targeted TherapyImmunotherapyHepatocellular Carcinoma (HCC)+2 more
Nanfang Hospital, Southern Medical University90 enrolled1 locationNCT07436845
Recruiting
Phase 2

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

Immunotherapy-related Pruritus
University of California, San Diego28 enrolled1 locationNCT06748404
Recruiting
Not Applicable

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy
University Hospital, Rouen100 enrolled1 locationNCT05689463
Recruiting
Phase 3

18F-FLUC PET/MR in Patients With Brain Mets

Brain MetastasisRadiation TherapyImmunotherapy, Active
University of Wisconsin, Madison30 enrolled1 locationNCT06159335